{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:19:02Z","timestamp":1792592342888,"version":"4.5.0"},"reference-count":61,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Primary biliary cholangitis (PBC) is a chronic, cholestatic, immune-mediated, and progressive liver disorder. Treatment to preventing the disease from advancing into later and irreversible stages is still an unmet clinical need. Accordingly, we set up a drug repurposing framework to find potential therapeutic agents targeting relevant pathways derived from an expanded pool of genes involved in different stages of PBC. Starting with updated human protein\u2013protein interaction data and genes specifically involved in the early and late stages of PBC, a network medicine approach was used to provide a PBC \u201cproximity\u201d or \u201cinvolvement\u201d gene ranking using network diffusion algorithms and machine learning models. The top genes in the proximity ranking, when combined with the original PBC-related genes, resulted in a final dataset of the genes most involved in PBC disease. Finally, a drug repurposing strategy was implemented by mining and utilizing dedicated drug\u2013gene interaction and druggable genome information knowledge bases (e.g., the DrugBank repository). We identified several potential drug candidates interacting with PBC pathways after performing an over-representation analysis on our initial 1121-seed gene list and the resulting disease-associated (algorithm-obtained) genes. The mechanism and potential therapeutic applications of such drugs were then thoroughly discussed, with a particular emphasis on different stages of PBC disease. We found that interleukin\/EGFR\/TNF-alpha inhibitors, branched-chain amino acids, geldanamycin, tauroursodeoxycholic acid, genistein, antioestrogens, curcumin, antineovascularisation agents, enzyme\/protease inhibitors, and antirheumatic agents are promising drugs targeting distinct stages of PBC. We developed robust and transparent selection mechanisms for prioritizing already approved medicinal products or investigational products for repurposing based on recognized unmet medical needs in PBC, as well as solid preliminary data to achieve this goal.<\/jats:p>","DOI":"10.3390\/biomedicines10071694","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T22:06:00Z","timestamp":1657749960000},"page":"1694","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Network Proximity-Based Drug Repurposing Strategy for Early and Late Stages of Primary Biliary Cholangitis"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4909-0436","authenticated-orcid":false,"given":"Endrit","family":"Shahini","sequence":"first","affiliation":[{"name":"National Institute of Research IRCCS \u201cSaverio De Bellis\u201d, Castellana Grotte, 70013 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0499-2292","authenticated-orcid":false,"given":"Giuseppe","family":"Pasculli","sequence":"additional","affiliation":[{"name":"Department of Computer, Control and Management Engineering Antonio Ruberti (DIAG), Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3456-9428","authenticated-orcid":false,"given":"Andrea","family":"Mastropietro","sequence":"additional","affiliation":[{"name":"Department of Computer, Control and Management Engineering Antonio Ruberti (DIAG), Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Stolfi","sequence":"additional","affiliation":[{"name":"National Research Council (CNR), Institute for Applied Computing (IAC), 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3635-7664","authenticated-orcid":false,"given":"Paolo","family":"Tieri","sequence":"additional","affiliation":[{"name":"National Research Council (CNR), Institute for Applied Computing (IAC), 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Vergni","sequence":"additional","affiliation":[{"name":"National Research Council (CNR), Institute for Applied Computing (IAC), 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Cozzolongo","sequence":"additional","affiliation":[{"name":"National Institute of Research IRCCS \u201cSaverio De Bellis\u201d, Castellana Grotte, 70013 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2882-4226","authenticated-orcid":false,"given":"Francesco","family":"Pesce","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation, Nephrology, Dialysis and Transplantation Unit, University of Bari \u201cA. Moro\u201d, 70121 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Giannelli","sequence":"additional","affiliation":[{"name":"National Institute of Research IRCCS \u201cSaverio De Bellis\u201d, Castellana Grotte, 70013 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J. Hepatol., 67, 145\u2013172.","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"14828","DOI":"10.1038\/ncomms14828","article-title":"A genome-wide association study identifies six novel risk loci for primary biliary cholangitis","volume":"8","author":"Qiu","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/17474124.2016.1216784","article-title":"Obeticholic acid for the treatment of primary biliary cirrhosis","volume":"10","author":"Jones","year":"2016","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2021.02.020","article-title":"Chronic fatigue should not be overlooked in primary biliary cholangitis","volume":"75","author":"Shahini","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients with Primary Biliary Cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2020.07.028","article-title":"Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis","volume":"74","author":"Frisch","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1111\/liv.14627","article-title":"Primary biliary cholangitis management: Controversies, perspectives and daily practice implications from an expert panel","volume":"40","author":"Alvaro","year":"2020","journal-title":"Liver Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/apt.12581","article-title":"Review article: Controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis","volume":"39","author":"Karlsen","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathol-020712-164014","article-title":"The immunobiology and pathophysiology of primary biliary cirrhosis","volume":"8","author":"Hirschfield","year":"2013","journal-title":"Annu. Rev. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"European Association For The Study Of The Liver (2009). EASL Clinical practice guidelines: Management of cholestatic liver diseases. J. Hepatol., 51, 237\u2013267.","DOI":"10.1016\/j.jhep.2009.04.009"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","first-page":"1257","article-title":"Primary biliary cirrhosis","volume":"60","author":"Scheuer","year":"1967","journal-title":"Proc. R. Soc. Med."},{"key":"ref_15","first-page":"D845","article-title":"The DisGeNET knowledge platform for disease genomics: 2019 update","volume":"48","author":"Ronzano","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"D535","DOI":"10.1093\/nar\/gkj109","article-title":"BioGRID: A general repository for interaction datasets","volume":"34","author":"Stark","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"ref_17","unstructured":"Tieri, P., Farina, L., Petti, M., Astolfi, L., Paci, P., and Castiglione, F. (2019). Encyclopedia of Bioinformatics and Computational Biology, Academic Press."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1489","DOI":"10.1002\/wsbm.1489","article-title":"Molecular networks in Network Medicine: Development and applications","volume":"12","author":"Silverman","year":"2020","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"ref_19","unstructured":"Stolfi, P., Mastropietro, A., Pasculli, G., Tieri, P., and Vergni, D. (2021). Adaptive Positive-Unlabelled Learning via Markov Diffusion. arXiv."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wu, S., Shao, F., Ji, J., Sun, R., Dong, R., Zhou, Y., Xu, S., Sui, Y., and Hu, J. (2015). Network Propagation with Dual Flow for Gene Prioritization. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0116505"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"W130","DOI":"10.1093\/nar\/gkx356","article-title":"WebGestalt 2017: A more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"545089","DOI":"10.3389\/fcell.2020.545089","article-title":"Designing a Network Proximity-Based Drug Repurposing Strategy for COVID-19","volume":"8","author":"Stolfi","year":"2020","journal-title":"Front Cell Dev. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00439-001-0615-0","article-title":"The HUGO Gene Nomenclature Committee (HGNC)","volume":"109","author":"Povey","year":"2001","journal-title":"Hum. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fcell.2019.00154","article-title":"What Is Nuclear Factor Kappa B (NF-\u03baB) Doing in and to the Mitochondrion?","volume":"7","author":"Albensi","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_25","first-page":"3951","article-title":"A study of regulatory effects of TLR4 and NF-\u03baB on primary biliary cholangitis","volume":"23","author":"Yu","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study","volume":"64","author":"Hirschfield","year":"2016","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"vi9","DOI":"10.1093\/rheumatology\/kez350","article-title":"Anakinra in children and adults with Still\u2019s disease","volume":"58","author":"Vastert","year":"2019","journal-title":"Rheumatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100107","DOI":"10.1016\/j.jtauto.2021.100107","article-title":"Baricitinib and primary biliary cholangitis","volume":"4","author":"Gordon","year":"2021","journal-title":"J. Transl. Autoimmun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/BF02213140","article-title":"Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study","volume":"41","author":"Crosignani","year":"1996","journal-title":"Dig. Dis. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2036.1997.124295000.x","article-title":"Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: A pilot crossover study","volume":"11","author":"Larghi","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e5391","DOI":"10.1097\/MD.0000000000005391","article-title":"A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis","volume":"95","author":"Ma","year":"2016","journal-title":"Medicine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2468-1253(19)30343-7","article-title":"Current and potential treatments for primary biliary cholangitis","volume":"5","author":"Shah","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_34","first-page":"CD002047","article-title":"Leflunomide for treating rheumatoid arthritis","volume":"2002","author":"Osiri","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.21741","article-title":"Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid","volume":"46","author":"Stojakovic","year":"2007","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/liv.12191","article-title":"Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis","volume":"33","author":"Cash","year":"2013","journal-title":"Liver Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/hep.31085","article-title":"Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?","volume":"72","author":"Lleo","year":"2020","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ahj.2003.09.003","article-title":"Inflammation as a therapeutic target: A unique role for abciximab","volume":"146","author":"Kereiakes","year":"2003","journal-title":"Am. Heart J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2165\/00003495-199651050-00010","article-title":"Muromonab CD3: A reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection","volume":"51","author":"Wilde","year":"1996","journal-title":"Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00534-010-0288-y","article-title":"Muromonab-CD3 therapy for refractory rejections after liver transplantation: A single-center experience during two decades in Japan","volume":"17","author":"Ueda","year":"2010","journal-title":"J. Hepatobiliary Pancreat Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12936-021-03750-x","article-title":"Longitudinal study based on a safety registry for malaria patients treated with artenimol-piperaquine in six European countries","volume":"20","author":"Vignier","year":"2021","journal-title":"Malar J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"112830","DOI":"10.1016\/j.ejmech.2020.112830","article-title":"Recent advances of podophyllotoxin\/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010\u20132020)","volume":"208","author":"Xiao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.chest.2020.09.077","article-title":"Etoposide as Salvage Therapy for Cytokine Storm Due to Coronavirus Disease 2019","volume":"159","author":"Patel","year":"2021","journal-title":"Chest"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s00535-018-1435-5","article-title":"The profiling of plasma free amino acids and the relationship between serum albumin and plasma-branched chain amino acids in chronic liver disease: A single-center retrospective study","volume":"53","author":"Sano","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Pieter Borg, P.C., Fekkes, D., Vrolijk, J.M., and van Buuren, H.R. (2005). The relation between plasma tyrosine concentration and fatigue in primary biliary cirrhosis and primary sclerosing cholangitis. BMC Gastroenterol., 5.","DOI":"10.1186\/1471-230X-5-11"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"21649","DOI":"10.1038\/s41598-021-01060-5","article-title":"p-STAT3 is a PDC-E2 interacting partner in human cholangiocytes and hepatocytes with potential pathobiological implications","volume":"11","author":"Kilanczyk","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.3389\/fimmu.2019.02815","article-title":"Abnormal Expression of ER\u03b1 in Cholangiocytes of Patients With Primary Biliary Cholangitis Mediated Intrahepatic Bile Duct Inflammation","volume":"10","author":"Cao","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/hep.21660","article-title":"Bile ductules and stromal cells express hedgehog ligands and\/or hedgehog target genes in primary biliary cirrhosis","volume":"45","author":"Jung","year":"2007","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/15548627.2019.1603547","article-title":"Emerging views of mitophagy in immunity and autoimmune diseases","volume":"16","author":"Xu","year":"2020","journal-title":"Autophagy"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Ghaffari, K., Pierce, L.X., Roufaeil, M., Gibson, I., Tae, K., Sahoo, S., Cantrell, J.R., Andersson, O., Lau, J., and Sakaguchi, T.F. (2021). NCK-associated protein 1 like (nckap1l) minor splice variant regulates intrahepatic biliary network morphogenesis. PLoS Genet., 17.","DOI":"10.1371\/journal.pgen.1009402"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0002-9440(10)65703-3","article-title":"Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis","volume":"153","author":"Kossakowska","year":"1998","journal-title":"Am. J. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"33052","DOI":"10.1038\/srep33052","article-title":"Curcumin protects ANIT-induced cholestasis through signaling pathway of FXR-regulated bile acid and inflammation","volume":"6","author":"Yang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jhep.2020.04.036","article-title":"Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults","volume":"73","author":"Halilbasic","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3389\/fimmu.2020.01567","article-title":"The Effects of Androgens on T Cells: Clues to Female Predominance in Autoimmune Liver Diseases?","volume":"11","author":"Henze","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3389\/fimmu.2019.01076","article-title":"Editorial: Sex Hormones and Gender Differences in Immune Responses","volume":"10","author":"Ortona","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/003655299750026100","article-title":"High prevalence of antibodies to calreticulin of the IgA class in primary biliary cirrhosis: A possible role of gut-derived bacterial antigens in its aetiology?","volume":"34","author":"Kreisel","year":"1999","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1006\/clin.1998.4542","article-title":"Complement system is not activated in primary biliary cirrhosis","volume":"87","author":"Gardinali","year":"1998","journal-title":"Clin. Immunol. Immunopathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1478-3231.2004.00920.x","article-title":"Tamoxifen: A novel treatment for primary biliary cirrhosis?","volume":"24","author":"Reddy","year":"2004","journal-title":"Liver Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1665-2681(19)31952-0","article-title":"Genistein decreases liver fibrosis and cholestasis induced by prolonged biliary obstruction in the rat","volume":"6","author":"Salas","year":"2007","journal-title":"Ann. Hepatol."},{"key":"ref_60","first-page":"79","article-title":"EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR","volume":"44","author":"Liu","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.30348","article-title":"The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis","volume":"69","author":"Uriarte","year":"2019","journal-title":"Hepatology"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1694\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:49:42Z","timestamp":1760140182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":61,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["biomedicines10071694"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10071694","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]}}}